EU Medical Device Tenders 2026: How to Win MDR-Compliant Healthcare Equipment Contracts

The MDR/IVDR Compliance Requirement

Since May 2021 (MDR) and May 2022 (IVDR), all medical devices placed on the EU market must comply with the new EU Medical Device Regulation. This is not just a market access requirement — it is directly embedded in EU public procurement selection criteria.

Contracting authorities typically require at minimum:

• Valid CE Declaration of Conformity under MDR 2017/745 or IVDR 2017/746
• Notified Body certificate (for Class IIa, IIb, III devices)
• Registration in EUDAMED (EU Medical Device Database) — being phased in, but increasingly required by buyers
• QMS certification: ISO 13485:2016 (Quality Management for Medical Devices) is standard

Devices that obtained CE marking under the old MDD/AIMD Directives have transitional periods running to 2027–2028 depending on device class. However, many contracting authorities are already requiring full MDR compliance to avoid mid-contract regulatory disruptions.

Medical Device Procurement Categories

Imaging and Diagnostic Equipment

MRI, CT, X-ray, ultrasound, and PET-CT systems represent the highest-value individual contracts — often €1M–€20M per lot. Major buyers: hospital networks, radiology departments, university hospitals. Qualification typically requires: manufacturer authorisation or sole distributor agreement, installation capability, CE certification, and 5-year service contract capability. CPV: 33111000–33118100.

Surgical Instruments and Operating Theatre Equipment

Laparoscopic instruments, electrosurgical devices, surgical robots (increasingly), anaesthesia equipment, and patient monitoring. Often awarded via multi-lot frameworks allowing hospitals to call off as needed. Robotic surgery (da Vinci equivalent procurement) is an emerging high-value category. CPV: 33162000–33169000.

Consumables and Single-Use Devices

Syringes, catheters, gloves, wound care, and IV consumables are procured via high-volume frameworks typically lasting 2–4 years. Central purchasing bodies aggregate demand across hundreds of hospitals. The volume is enormous — CONSIP's consumables frameworks can exceed €500M. Margins are thin but volume makes them strategically important. CPV: 33141000–33141900.

In Vitro Diagnostics (IVD)

Laboratory analysers, reagent kits, point-of-care testing devices, and molecular diagnostics. Post-COVID IVD procurement remains elevated. IVDR compliance is mandatory — IVDR has stricter requirements than the old IVDD, and many legacy products are still transitioning. CPV: 33696500 (reagents), 38434500 (biochemistry analysers).

National Framework Agreements: The Strategic Priority

In medical device procurement, framework agreements through Central Purchasing Bodies (CPBs) are more valuable than individual hospital tenders. A single CPB framework award can generate hundreds of call-offs over 4 years without re-tendering.

EU Joint Procurement: HERA and Critical Medical Countermeasures

The Health Emergency Preparedness and Response Authority (HERA) now operates an EU Joint Procurement Agreement (JPA) for medical countermeasures — initially for pandemic preparedness but expanding to critical devices and pharmaceuticals. Participating member states can leverage HERA framework tenders rather than running national procedures. For suppliers, qualifying for HERA-adjacent frameworks gives pan-EU access through a single qualification exercise.

Award Criteria in Medical Device Tenders

Medical device evaluation is increasingly MEAT-driven (Most Economically Advantageous Tender), not price-only. Typical evaluation weightings:

• Price: 30–50% (lower for complex devices, higher for commoditised consumables)
• Technical quality: 20–35% (device performance specifications, clinical data)
• After-sales service: 15–25% (response time, parts availability, training)
• Environmental: 5–15% (packaging, energy consumption, end-of-life disposal)
• Interoperability: 5–10% (HL7 FHIR, HL7 v2 integration with hospital HIS/RIS)

Win Strategy for Medical Device Vendors

Prioritise CPB framework qualification above all else. Individual hospital tenders are high-effort, low-volume. CPB frameworks are harder to qualify for but generate consistent revenue across entire national health systems.

Complete EUDAMED registration proactively. Even though registration timelines are phased, buyers increasingly check EUDAMED status. Early registration signals compliance maturity and removes a common disqualification risk.

Invest in clinical evidence documentation. MEAT criteria increasingly include clinical performance data beyond CE certification. Post-market clinical follow-up (PMCF) data that demonstrates real-world outcomes scores well in quality evaluations.

Build FHIR integration capability. The European Health Data Space (EHDS) regulation is driving FHIR R4 adoption across EU health systems. Devices that integrate natively with hospital EHR systems via FHIR score higher in interoperability criteria — and this advantage will only grow.